Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 343 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... October 29, 2020 Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk? February 1, 2024 Emma Stone Motivated to Help Others After Her Mother Was Diagnosed... November 16, 2020 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Load more HOT NEWS ¿Tener paneles solares o vivir cerca de una granja solar puede... NCI-MATCH Update: More Labs, New Arms, and Initial Findings ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways Blood Test for Early Detection of Cancer: Final Study Results Support...
